Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging - PubMed (original) (raw)
Clinical Trial
. 2002 Sep 15;20(18):3826-40.
doi: 10.1200/JCO.2002.09.144.
Affiliations
- PMID: 12228202
- DOI: 10.1200/JCO.2002.09.144
Clinical Trial
Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging
Susan M Galbraith et al. J Clin Oncol. 2002.
Abstract
Purpose: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) causes vascular shutdown in preclinical models. Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) studies were performed in the phase I trials to examine changes related to blood flow and permeability in tumor and muscle.
Patients and methods: Sixteen patients treated with DMXAA from 500 to 4,900 mg/m(2) had DCE-MRI examinations before and after treatment. The maximum gradient, the maximum enhancement, and the area under the signal-intensity-time curve (AUC) over the first 90 seconds were calculated for each pixel in regions of interest (ROIs) in muscle and tumor, and the median value for each ROI was obtained. Changes after treatment were compared with 95% limits of agreement for an individual and for groups using data from our reproducibility study.
Results: Nine of 16 patients had significant reductions in AUC 24 hours after the first dose of DMXAA, and eight of 11 patients had reductions of up to 66% in AUC 24 hours after the last dose. Mean reductions in gradient, enhancement, and AUC were 25%, 18%, and 31%, respectively, 24 hours after the last dose, significantly greater than the 95% limits of change for a group of 11 patients. Enhancement and AUC in muscle 24 hours after the first dose were significantly reduced, but no significant changes were seen 24 hours after the last dose.
Conclusion: DMXAA significantly reduces DCE-MRI parameters related to tumor blood flow, over a wide dose range, consistent with the reported tumor vascular targeting activity. Further clinical evaluation of DMXAA is warranted.
Similar articles
- Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis.
Galbraith SM, Lodge MA, Taylor NJ, Rustin GJ, Bentzen S, Stirling JJ, Padhani AR. Galbraith SM, et al. NMR Biomed. 2002 Apr;15(2):132-42. doi: 10.1002/nbm.731. NMR Biomed. 2002. PMID: 11870909 - 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M, Jameson MB. McKeage MJ, et al. Clin Cancer Res. 2006 Mar 15;12(6):1776-84. doi: 10.1158/1078-0432.CCR-05-1939. Clin Cancer Res. 2006. PMID: 16551862 Clinical Trial. - 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Zhou S, Kestell P, Baguley BC, Paxton JW. Zhou S, et al. Invest New Drugs. 2002 Aug;20(3):281-95. doi: 10.1023/a:1016215015530. Invest New Drugs. 2002. PMID: 12201491 Review. - Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study.
Mendichovszky IA, Cutajar M, Gordon I. Mendichovszky IA, et al. Eur J Radiol. 2009 Sep;71(3):576-81. doi: 10.1016/j.ejrad.2008.09.025. Epub 2008 Nov 11. Eur J Radiol. 2009. PMID: 19004588 - Antivascular therapy of cancer: DMXAA.
Baguley BC. Baguley BC. Lancet Oncol. 2003 Mar;4(3):141-8. doi: 10.1016/s1470-2045(03)01018-0. Lancet Oncol. 2003. PMID: 12623359 Review.
Cited by
- Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats.
Bradley DP, Tessier JJ, Ashton SE, Waterton JC, Wilson Z, Worthington PL, Ryan AJ. Bradley DP, et al. Neoplasia. 2007 May;9(5):382-91. doi: 10.1593/neo.07145. Neoplasia. 2007. PMID: 17534443 Free PMC article. - 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study.
Rustin GJ, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, Bellenger K, Gumbrell L, Folkes L, Halbert G; Phase I/II Trials Committee of Cancer Research UK. Rustin GJ, et al. Br J Cancer. 2003 Apr 22;88(8):1160-7. doi: 10.1038/sj.bjc.6600885. Br J Cancer. 2003. PMID: 12698178 Free PMC article. Clinical Trial. - Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhao L, Marshall ES, Kelland LR, Baguley BC. Zhao L, et al. Invest New Drugs. 2007 Jun;25(3):271-6. doi: 10.1007/s10637-006-9029-0. Epub 2007 Jan 3. Invest New Drugs. 2007. PMID: 17203401 - Multiparametric Quantitative Imaging Biomarker as a Multivariate Descriptor of Health: A Roadmap.
Raunig DL, Pennello GA, Delfino JG, Buckler AJ, Hall TJ, Guimaraes AR, Wang X, Huang EP, Barnhart HX, deSouza N, Obuchowski N. Raunig DL, et al. Acad Radiol. 2023 Feb;30(2):159-182. doi: 10.1016/j.acra.2022.10.026. Epub 2022 Dec 1. Acad Radiol. 2023. PMID: 36464548 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources